Among patients with curatively resected early-stage biliary tract cancer (BTC), recent study findings from a real-world cohort trial revealed the value of circulating tumor DNA (ctDNA) as a prognostic ...
At ctDNA levels below 10 mutant copies/mL (0.25% VAF) it can reassure patients that progression is unlikely, while levels above 100 copies/mL (2.5% VAF) are associated with at least a 90% chance ...
circulating tumor DNA (ctDNA), which is released into the bloodstream by tumor cells, offers a promising non-invasive alternative. It allows for real-time monitoring and comprehensive genetic ...
Natera (NTRA) announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA or ctDNA. This builds on ...
National Comprehensive Cancer Network® (NCCN®) Guidelines for colon and rectal cancer were updated to include ctDNA as a prognostic marker and high risk factor for recurrence NCCN guideline for ...
ctDNA offers a non-invasive way to track Multiple Myeloma, reducing the need for painful bone marrow biopsies Detects genetic mutations, treatment resistance, and disease progression before ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results